€22.95
1.71%
Xetra, Apr 17, 05:35 pm CET
ISIN
DE000A1EWVY8
Symbol
FYB
Index
Sector
Industry

Formycon Stock price

€22.95
-4.45 16.24% 1M
-29.05 55.87% 6M
-30.15 56.78% YTD
-17.25 42.91% 1Y
-43.05 65.23% 3Y
+3.05 15.33% 5Y
-8.05 25.97% 10Y
Xetra, Closing price Thu, Apr 17 2025
-0.40 1.71%
ISIN
DE000A1EWVY8
Symbol
FYB
Index
Sector
Industry

Key metrics

Market capitalization €405.40m
Enterprise Value €374.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.37
P/S ratio (TTM) P/S ratio 5.82
P/B ratio (TTM) P/B ratio 0.88
Revenue growth (TTM) Revenue growth -10.32%
Revenue (TTM) Revenue €69.67m
EBIT (operating result TTM) EBIT €-22.98m
Free Cash Flow (TTM) Free Cash Flow €-24.50m
EPS (TTM) EPS €-7.13
P/E forward negative
P/S forward 7.30
EV/Sales forward 6.73
Show more

Is Formycon a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Formycon Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Formycon forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Formycon forecast:

Buy
89%
Hold
11%

Financial data from Formycon

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
70 70
10% 10%
100%
- Direct Costs 55 55
1% 1%
79%
15 15
36% 36%
21%
- Selling and Administrative Expenses 12 12
9% 9%
17%
- Research and Development Expense 17 17
80% 80%
24%
-13 -13
1,002% 1,002%
-19%
- Depreciation and Amortization 9.81 9.81
419% 419%
14%
EBIT (Operating Income) EBIT -23 -23
5,269% 5,269%
-33%
Net Profit -126 -126
266% 266%
-180%

In millions EUR.

Don't miss a Thing! We will send you all news about Formycon directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Formycon Stock News

AD HOC NEWS
24 days ago
Hohe Abschreibungen haben dem Biotechnologie-Unternehmen Formycon DE000A1EWVY8 im vergangenen Jahr erwartungsgemäß rote Zahlen eingebrockt.
AD HOC NEWS
24 days ago
Hohe Abschreibungen haben dem Biotechnologie-Unternehmen Formycon DE000A1EWVY8 im vergangenen Jahr wie befürchtet rote Zahlen eingebrockt.
More Formycon News

Company Profile

Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205 which focusoin the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.

Head office Germany
CEO Stefan Glombitza
Employees 250
Founded 2007
Website formycon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today